During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- Genetically engineered T cells for cancer immunotherapyon September 19, 2019 at 3:13 pm
T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this ...
- E-sniffer predicts non-responders to lung cancer immunotherapyon September 19, 2019 at 2:20 pm
An electronic “nose” that detects chemicals in the breath of lung cancer patients may help distinguish between those who will and will not respond to immunotherapy, a new study suggests. In the small ...
- Global Cancer Immunotherapy Market 2025: Growing With Novartis AG, Bristol Mayers Squibb, Johnson and Johnson, Merck KgaA, Eli Lillyon September 19, 2019 at 9:02 am
Sep 19, 2019 (The Expresswire) -- Complete report on The Global Cancer Immunotherapy Market 2025 Research Report is spread across 350 pages, Top profiling companies and supported with tables and ...
- Combination therapy shows promise against fast-growing lung canceron September 18, 2019 at 10:07 pm
Overall, lung cancer kills about 150,000 people annually, according to the Centers for Disease Control and Prevention. RELATED Antibiotics prior to immunotherapy lower survival rate for cancer ...
- Cancer Immunotherapy Market 2019 Outlook, Opportunity and Demand Analysis Report by 2024on September 18, 2019 at 6:57 am
Sep 18, 2019 (Heraldkeepers) -- New York, September 18, 2019: Immunotherapy is a treatment which uses particular parts of person's immune organism to fight against cancer. Immune system is a ...
- Breathalyzer Sniffs Out Potential Cancer Immunotherapy Responderson September 18, 2019 at 6:12 am
A prospective observational trial in patients with advanced non-small cell lung cancer (NSCLC) has found that an electronic nose device that detects chemicals in the breath can identify with 85% ...
- Electronic nose can sniff out which lung cancer patients will respond to immunotherapyon September 17, 2019 at 11:42 pm
An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research ...
- Radiation May Boost Immunotherapy in Metastatic Lung Canceron September 17, 2019 at 10:49 am
CHICAGO — Adding stereotactic body radiotherapy (SBRT) to the treatment regimen increased progression-free survival (PFS) in some patients with metastatic non-small cell lung cancer (NSCLC) in what ...
- Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapyon September 17, 2019 at 8:02 am
NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced ...
- Antibiotics prior to immunotherapy lower survival rate for cancer patients, study sayson September 13, 2019 at 10:32 am
Sept. 13 (UPI) --While antibiotics fight off infections, they can lower survival rates for patients receiving immunotherapy for cancer, a new study says. Patients who took antibiotics before starting ...
via Google News and Bing News